Contrast Media-Enhanced Breast Computed Tomography With a Photon-Counting Detector: Initial Experiences on In Vivo Image Quality and Correlation to Histology

Detectability of Breast Cancer in Dedicated Breast CT Compared With Mammography Dependent on Breast Density

OBJECTIVES

To evaluate the detectability of non-contrast-enhanced and contrast-enhanced spiral breast computed tomography ([non]-CE-SBCT) compared with mammography. Secondary objectives are to determine detectability depending on breast density and to evaluate appearance of breast malignancies according to BI-RADS descriptors.

METHODS

This retrospective institutional review board-approved study included 90 women with 105 biopsy-proven malignant breast lesions. Breast density, BI-RADS descriptors, and detectability were evaluated by 2 independent readers. Diagnostic confidence was rated on a 4-point Likert scale.

RESULTS

For readers 1 and 2, detectability was 83.8% and 80.0% for mammography, 99.1% and 99.1% for CE-SBCT ( P < 0.05), and 66.7% and 61.9% for non-CE-SBCT ( P < 0.05). With both readers, detectability in CE-SBCT was high for density A/B/C/D (both 100%/100%/100%/87.5%). Detectability of readers declined with increasing density for mammography (density A = 100%, B = 89.1% and 95.1%, C = 73.1%, D = 50.0% and 71.4%; P < 0.05) and for non-CE-SBCT (density A = 87.5% and 90.7%, B = 65.5% and 69.1%, C = 54.8% and 60.0%, D = 37.5%; P < 0.05). Mass lesions were detected with CT as often as with mammography, whereas architectural distortions and microcalcifications were detected less often with SBCT. Diagnostic confidence was very high or high in 97.2% for CE-SBCT, in 74.1% for non-CE-SBCT, and in 81.4% for mammography.

CONCLUSIONS

Detectability and diagnostic confidence were very high in CE-SBCT, regardless of breast density. The detectability of non-CE-SBCT was lower than that of mammography and declined with increasing breast density.

Diagnostic Accuracy of Contrast-Enhanced Thoracic Photon-Counting Computed Tomography for Opportunistic Locoregional Staging of Breast Cancer Compared With Digital Mammography: A Prospective Trial

OBJECTIVE

Accurate locoregional staging is crucial for effective breast cancer treatment. Photon-counting computed tomography (PC-CT) is an emerging technology with high spatial resolution and the ability to depict uptake of contrast agents in tissues, making it a promising tool for breast cancer imaging. The aim of this study was to establish the feasibility of locoregional staging of breast cancer through contrast-enhanced thoracic PC-CT, assess its diagnostic performance, and compare it with that of digital mammography (DM).

MATERIALS AND METHODS

Patients with newly diagnosed breast cancer, DM, and indication of thoracic CT staging were prospectively enrolled in this clinical cohort study over a period of 6 months. Participants underwent contrast-enhanced thoracic PC-CT and breast magnetic resonance imaging in prone position. After blinding to patient data, 2 radiologists independently rated PC-CT and DM regarding the following 6 characteristics: (1) diameter of the largest mass lesion, (2) infiltration of cutis/pectoral muscle/thoracic wall, (3) number of mass lesions, (4) presence/absence of adjacent ductal carcinoma in situ (DCIS), (5) tumor conspicuity, and (6) diagnostic confidence. Reference standard was generated from consensus reading of magnetic resonance imaging combined with all histopathological/clinical data by an independent adjudication committee applying TNM eighth edition.

RESULTS

Among 32 enrolled female subjects (mean ± SD age, 59 ± 13.0 years), diagnostic accuracy for T-classification was higher for PC-CT compared with DM (0.94 vs 0.50, P < 0.01). Moreover, the correlation of the number of detected tumor masses with the reference standard was stronger for PC-CT than for DM (0.72 vs 0.50, P < 0.01). We observed that PC-CT significantly ( P < 0.04) outperformed DM regarding not only sensitivity (0.83 and 0.25, respectively) but also specificity (0.99 and 0.80, respectively) for adjacent DCIS. The κ values for interreader reliability were higher for PC-CT compared with DM (mean 0.88 vs 0.54, respectively; P = 0.01).

CONCLUSIONS

Photon-counting computed tomography outperformed DM in T-classification and provided higher diagnostic accuracy for the detection of adjacent DCIS. Therefore, opportunistic locoregional staging of breast cancer in contrast-enhanced thoracic PC-CT is feasible and could overcome limitations of DM with the potential to improve patient management.

Contrast-enhanced Mammography versus MR Imaging of the Breast

Breast MR imaging and contrast-enhanced mammography (CEM) are both techniques that employ intravenously injected contrast agent to assess breast lesions. This approach is associated with a very high sensitivity for malignant lesions that typically exhibit rapid enhancement due to the leakiness of neovasculature. CEM may be readily available at the breast imaging department and can be performed on the spot. Breast MR imaging provides stronger enhancement than the x-ray-based techniques and offers higher sensitivity. From a patient perspective, both modalities have their benefits and downsides; thus, patient preference could also play a role in the selection of the imaging technique.

Dedicated Photon-Counting CT for Detection and Classification of Microcalcifications: An Intraindividual Comparison With Digital Breast Tomosynthesis

OBJECTIVES

Clinical experience regarding the use of dedicated photon-counting breast CT (PC-BCT) for diagnosis of breast microcalcifications is scarce. This study systematically compares the detection and classification of breast microcalcifications using a dedicated breast photon-counting CT, especially designed for examining the breast, in comparison with digital breast tomosynthesis (DBT).

MATERIALS AND METHODS

This is a prospective intraindividual study on women with DBT screening-detected BI-RADS-4/-5 microcalcifications who underwent PC-BCT before biopsy. PC-BCT images were reconstructed with a noninterpolated spatial resolution of 0.15 × 0.15 × 0.15 mm (reconstruction mode 1 [RM-1]) and with 0.3 × 0.3 × 0.3 mm (reconstruction mode 2 [RM-2]), plus thin-slab maximum intensity projection (MIP) reconstructions. Two radiologists independently rated the detection of microcalcifications in direct comparison with DBT on a 5-point scale. The distribution and morphology of microcalcifications were then rated according to BI-RADS. The size of the smallest discernible microcalcification particle was measured. For PC-BCT, the average glandular dose was determined by Monte Carlo simulations; for DBT, the information provided by the DBT system was used.

RESULTS

Between September 2022 and July 2023, 22 participants (mean age, 61; range, 42-85 years) with microcalcifications (16 malignant; 6 benign) were included. In 2/22 with microcalcifications in the posterior region, microcalcifications were not detectable on PC-BCT, likely because they were not included in the PC-BCT volume. In the remaining 20 participants, microcalcifications were detectable. With high between-reader agreement (κ > 0.8), conspicuity of microcalcifications was rated similar for DBT and MIPs of RM-1 (mean, 4.83 ± 0.38 vs 4.86 ± 0.35) (P = 0.66), but was significantly lower (P < 0.05) for the remaining PC-BCT reconstructions: 2.11 ± 0.92 (RM-2), 2.64 ± 0.80 (MIPs of RM-2), and 3.50 ± 1.23 (RM-1). Identical distribution qualifiers were assigned for PC-BCT and DBT in 18/20 participants, with excellent agreement (κ = 0.91), whereas identical morphologic qualifiers were assigned in only 5/20, with poor agreement (κ = 0.44). The median size of smallest discernible microcalcification particle was 0.2 versus 0.6 versus 1.1 mm in DBT versus RM-1 versus RM-2 (P < 0.001), likely due to blooming effects. Average glandular dose was 7.04 mGy (PC-BCT) versus 6.88 mGy (DBT) (P = 0.67).

CONCLUSIONS

PC-BCT allows reliable detection of in-breast microcalcifications as long as they are not located in the posterior part of the breast and allows assessment of their distribution, but not of their individual morphology.

Photon-counting computed tomography - clinical application in oncological, cardiovascular, and pediatric radiology

BACKGROUND

 Photon-counting detector computed tomography (PCD-CT) is a promising new technology with the potential to fundamentally change workflows in the daily routine and provide new quantitative imaging information to improve clinical decision-making and patient management.

METHOD

 The contents of this review are based on an unrestricted literature search of PubMed and Google Scholar using the search terms "photon-counting CT", "photon-counting detector", "spectral CT", "computed tomography" as well as on the authors' own experience.

RESULTS

 The fundamental difference with respect to the currently established energy-integrating CT detectors is that PCD-CT allows for the counting of every single photon at the detector level. Based on the identified literature, PCD-CT phantom measurements and initial clinical studies have demonstrated that the new technology allows for improved spatial resolution, reduced image noise, and new possibilities for advanced quantitative image postprocessing.

CONCLUSION

 For clinical practice, the potential benefits include fewer beam hardening artifacts, a radiation dose reduction, and the use of new or combinations of contrast agents. In particular, critical patient groups such as oncological, cardiovascular, lung, and head & neck as well as pediatric patient collectives benefit from the clinical advantages.

KEY POINTS

  · Photon-counting computed tomography (PCD-CT) is being used for the first time in routine clinical practice, enabling a significant dose reduction in critical patient populations such as oncology, cardiology, and pediatrics.. · Compared to conventional CT, PCD-CT enables a reduction in electronic image noise.. · Due to the spectral data sets, PCD-CT enables fully comprehensive post-processing applications..

CITATION FORMAT

· Hagen F, Soschynski M, Weis M et al. Photon-counting computed tomography - clinical application in oncological, cardiovascular, and pediatric radiology. Fortschr Röntgenstr 2024; 196: 25 - 34.

Photon Counting CT: Technical Principles, Clinical Applications, and Future Prospects

Photon-counting computed tomography (PCCT) is a new technique that utilizes photon-counting detectors to convert individual X-ray photons directly into an electrical signal, which can achieve higher spatial resolution, improved iodine signal, radiation dose reduction, artifact reduction, and multienergy imaging. This review introduces the technical principles of PCCT, and summarizes its first-in-human experience and current applications in clinical settings, and discusses the future prospects of PCCT.

Feasibility of In Vivo Metal Artifact Reduction in Contrast-Enhanced Dedicated Spiral Breast Computed Tomography

BACKGROUND

Radiopaque breast markers cause artifacts in dedicated spiral breast-computed tomography (SBCT). This study investigates the extent of artifacts in different marker types and the feasibility of reducing artifacts through a metal artifact reduction (MAR) algorithm.

METHODS

The pilot study included 18 women who underwent contrast-enhanced SBCT. In total, 20 markers of 4 different types were analyzed for artifacts. The extent of artifacts with and without MAR was measured via the consensus of two readers. Image noise was quantitatively evaluated, and the effect of MAR on the detectability of breast lesions was evaluated on a 3-point Likert scale.

RESULTS

Breast markers caused significant artifacts that impaired image quality and the detectability of lesions. MAR decreased artifact size in all analyzed cases, even in cases with multiple markers in a single slice. The median length of in-plain artifacts significantly decreased from 31 mm (range 11-51 mm) in uncorrected to 2 mm (range 1-5 mm) in corrected images (p ≤ 0.05). Artifact size was dependent on marker size. Image noise in slices affected by artifacts was significantly lower in corrected (13.6 ± 2.2 HU) than in uncorrected images (19.2 ± 6.8 HU, p ≤ 0.05). MAR improved the detectability of lesions affected by artifacts in 5 out of 11 cases.

CONCLUSION

MAR is feasible in SBCT and improves the image quality and detectability of lesions.

Computed Tomography 2.0: New Detector Technology, AI, and Other Developments

ABSTRACT

Computed tomography (CT) dramatically improved the capabilities of diagnostic and interventional radiology. Starting in the early 1970s, this imaging modality is still evolving, although tremendous improvements in scan speed, volume coverage, spatial and soft tissue resolution, as well as dose reduction have been achieved. Tube current modulation, automated exposure control, anatomy-based tube voltage (kV) selection, advanced x-ray beam filtration, and iterative image reconstruction techniques improved image quality and decreased radiation exposure. Cardiac imaging triggered the demand for high temporal resolution, volume acquisition, and high pitch modes with electrocardiogram synchronization. Plaque imaging in cardiac CT as well as lung and bone imaging demand for high spatial resolution. Today, we see a transition of photon-counting detectors from experimental and research prototype setups into commercially available systems integrated in patient care. Moreover, with respect to CT technology and CT image formation, artificial intelligence is increasingly used in patient positioning, protocol adjustment, and image reconstruction, but also in image preprocessing or postprocessing. The aim of this article is to give an overview of the technical specifications of up-to-date available whole-body and dedicated CT systems, as well as hardware and software innovations for CT systems in the near future.

Dedicated breast computed-tomography in women with a personal history of breast cancer: A proof-of-concept study

PURPOSE

To compare the subjective image quality assessment using B-CT and digital mammography in women with personal history of breast cancer (PHBC).

METHOD

In this retrospective study 32 patients with PHBC were included. Each patient had undergone a B-CT examination and a previous mammogram in a time interval of less than 18 months between the two examinations. Two radiologists evaluated the two examinations independently with regard to the presence of lesions, BI-RADS classification, level of confidence for the overall exam interpretation, scar evaluation and image quality including image degradation due to clip artifacts. Level of confidence and image quality were assessed using a 5-point Likert scale. A p-value of less than 0.01 was considered statistically significant.

RESULTS

Thirty-seven operated and 27 non-operated breasts were included. Confidence for the overall interpretation with B-CT was equal or superior to mammography in 63 cases (98.4 %) for reader 1 and in 58 cases (90.6 %) for reader 2 (p <.001). Confidence for scar evaluation with B-CT was equal or superior to mammography in all cases for reader 1 and in 34 cases (91.9 %) for readers 2 (p <.001). One case with local recurrence in B-CT was identified by both readers and no false positive findings were reported. A moderate to high image degradation due to beam-hardening artifacts has been reported by both readers in 29.4 % of cases due to surgical clips in the B-CT volume.

CONCLUSIONS

B-CT in patients with PHBC provides high quality images that can be evaluated with confidence equal or superior to mammography.